Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPACA: Phase 2 Study of Lepodisiran in Elevated Lp(a)
NCT05565742Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2022
- Primary completion
- Oct 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 10
01
Overview
A Phase 2 trial of lepodisiran in elevated lipoprotein(a) (Lp(a)), sponsored by Eli Lilly and Company. Started Oct 2022; status: completed.
02
Drugs
lepodisiran
03
Conditions
elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT05565742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05565742.